Top

Published in:

01-05-2014 | Original Paper

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

Authors: Eduardo Martínez-Morillo, Oskar Hansson, Yuka Atagi, Guojun Bu, Lennart Minthon, Eleftherios P. Diamandis, Henrietta M. Nielsen

Published in: Acta Neuropathologica | Issue 5/2014

Abstract

The apolipoprotein E (ApoE) ε4 allele is the strongest risk factor of sporadic Alzheimer’s disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE ε2, ε3, ε4) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE ε4 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and Aβ1-42 of which the latter association was weaker and only present in APOE ε4 carriers indicating a differential involvement of ApoE in tau versus Aβ-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE ɛ4 carriers and whether this decrease in plasma ApoE predisposes APOE ɛ4 carriers to AD.

Available only for authorised users

Blennow K, Fredman P, Wallin A et al (1993) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 33:129–133PubMedCrossRef

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231–245. doi:10.1007/BF02815140 PubMedCrossRef

Castellano JM, Kim J, Stewart FR et al (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3:89ra57. doi:10.1126/scitranslmed.3002156

Corder EH, Saunders AM, Risch NJ et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180–184PubMedCrossRef

Cramer PE, Cirrito JR, Wesson DW et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506. doi:10.1126/science.1217697 PubMedCentralPubMedCrossRef

Cruchaga C, Kauwe JS, Nowotny P et al (2012) Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Genet 21:4558–4571. doi:10.1093/hmg/dds296 PubMedCentralPubMedCrossRef

Darreh-Shori T, Forsberg A, Modiri N et al (2011) Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer’s disease in the brain in vivo. Neurobiol Aging 32(2320):e2315–e2332. doi:10.1016/j.neurobiolaging.2010.04.028

Fagan AM, Mintun MA, Mach RH et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512–519. doi:10.1002/ana.20730 PubMedCrossRef

Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278:1349–1356PubMedCrossRef

10.

Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78:815–821. doi:10.1172/JCI112645 PubMedCentralPubMedCrossRef

11.

Gupta VB, Laws SM, Villemagne VL et al (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76:1091–1098. doi:10.1212/WNL.0b013e318211c352 PubMedCrossRef

12.

Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E structure: insights into function. Trends Biochem Sci 31:445–454. doi:10.1016/j.tibs.2006.06.008 PubMedCrossRef

13.

Hegele RA (2009) Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 10:109–121. doi:10.1038/nrg2481 PubMedCrossRef

14.

Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548PubMed

15.

Hudry E, Dashkoff J, Roe AD et al (2013) Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5:212ra161. doi:10.1126/scitranslmed.3007000

16.

Kok E, Haikonen S, Luoto T et al (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65:650–657. doi:10.1002/ana.21696 PubMedCrossRef

17.

LaClair KD, Manaye KF, Lee DL et al (2013) Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener 8:18. doi:10.1186/1750-1326-8-18 PubMedCentralPubMedCrossRef

18.

Lahoz C, Schaefer EJ, Cupples LA et al (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154:529–537. doi:10.1016/S0021-9150(00)00570-0 PubMedCrossRef

19.

Linton MF, Gish R, Hubl ST et al (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 88:270–281. doi:10.1172/JCI115288 PubMedCentralPubMedCrossRef

20.

Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. doi:10.1038/nrneurol.2012.263 PubMedCentralPubMedCrossRef

21.

Liu M, Kuhel DG, Shen L, Hui DY, Woods SC (2012) Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol 303:R903–R908. doi:10.1152/ajpregu.00219.2012 PubMedCentralPubMedCrossRef

22.

Ly S, Altman R, Petrlova J et al (2013) Binding of apolipoprotein E inhibits the oligomer growth of amyloid-beta peptide in solution as determined by fluorescence cross-correlation spectroscopy. J Biol Chem 288:11628–11635. doi:10.1074/jbc.M112.411900 PubMedCrossRef

23.

Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1:507–537. doi:10.1146/annurev.genom.1.1.507

24.

Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50(Suppl):S183–S188. doi:10.1194/jlr.R800069-JLR200 PubMedCentralPubMed

25.

Martinez-Morillo E, Nielsen HM, Batruch I et al (2014) Assessment of Peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res 13:1077–1087. doi:10.1021/pr401060x PubMedCrossRef

26.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMedCrossRef

27.

McKhann G (1987) Diagnostics and statistical manual of mental disorders. American Psychiatric Association, Arlington

28.

Mooijaart SP, Berbee JF, van Heemst D et al (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3: e176. doi:10.1371/journal.pmed.0030176

29.

Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R (2014) Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 62:493–503. doi:10.1002/glia.22619 PubMedCrossRef

30.

Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R (2010) Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58:1235–1246. doi:10.1002/glia.21004 PubMed

31.

Riddell DR, Zhou H, Atchison K et al (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28:11445–11453PubMedCrossRef

32.

Rosen C, Hansson O, Blennow K, Zetterberg H (2013) Fluid biomarkers in Alzheimer’s disease—current concepts. Mol Neurodegener 8:20. doi:10.1186/1750-1326-8-20 PubMedCentralPubMedCrossRef

33.

Sanan DA, Weisgraber KH, Russell SJ et al (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860–869. doi:10.1172/JCI117407 PubMedCentralPubMedCrossRef

34.

Schmidt C, Becker H, Zerr I (2014) Cerebrospinal fluid apolipoprotein e concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer’s disease. Am J Alzheimers Dis Other Demen 29:54–60. doi:10.1177/1533317513505133 PubMedCrossRef

35.

Shinohara M, Petersen RC, Dickson DW, Bu G (2013) Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 125:535–547. doi:10.1007/s00401-013-1086-9 PubMedCentralPubMedCrossRef

36.

Simon R, Girod M, Fonbonne C et al (2012) Total ApoE and ApoE4 isoform assays in an Alzheimer’s disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 11:1389–1403. doi:10.1074/mcp.M112.018861 PubMedCentralPubMedCrossRef

37.

Small BJ, Rosnick CB, Fratiglioni L, Backman L (2004) Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 19:592–600. doi:10.1037/0882-7974.19.4.592

38.

Smit M, de Knijff P, Rosseneu M et al (1988) Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 80:287–292PubMedCrossRef

39.

Song F, Poljak A, Crawford J et al (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE 7:e34078. doi:10.1371/journal.pone.0034078 PubMedCentralPubMedCrossRef

40.

Toledo JB, Da X, Weiner MW et al (2014) CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. doi:10.1007/s00401-013-1236-0 PubMedCentral

41.

Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70:223–228. doi:10.1001/jamaneurol.2013.600 PubMedCentralPubMedCrossRef

42.

Vance JE, Hayashi H (2010) Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 1801:806–818. doi:10.1016/j.bbalip.2010.02.007 PubMedCrossRef

43.

Vanderstichele H, Van Kerschaver E, Hesse C et al (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7:245–258PubMedCrossRef

44.

Vanmechelen E, Vanderstichele H, Davidsson P et al (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52. doi:10.1016/S0304-3940(00)01036-3 PubMedCrossRef

45.

Veerhuis R, Boshuizen RS, Familian A (2005) Amyloid associated proteins in Alzheimer’s and prion disease. Curr Drug Targets CNS Neurol Disord 4:235–248PubMedCrossRef

46.

Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10:241–252. doi:10.1016/S1474-4422(10)70325-2 PubMedCentralPubMedCrossRef

47.

Verghese PB, Castellano JM, Garai K et al (2013) ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA 110:E1807–E1816. doi:10.1073/pnas.1220484110 PubMedCentralPubMedCrossRef

48.

Ward A, Crean S, Mercaldi CJ et al (2012) Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology 38:1–17. doi:10.1159/000334607 PubMedCrossRef

49.

Wennstrom M, Surova Y, Hall S et al (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8:e53250. doi:10.1371/journal.pone.0053250 PubMedCentralPubMedCrossRef

50.

Wildsmith KR, Basak JM, Patterson BW et al (2012) In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS ONE 7:e38013. doi:10.1371/journal.pone.0038013 PubMedCentralPubMedCrossRef

51.

Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70:440–444. doi:10.1001/jamaneurol.2013.2152 PubMedCrossRef

Title: Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls
Authors: Eduardo Martínez-Morillo
Oskar Hansson
Yuka Atagi
Guojun Bu
Lennart Minthon
Eleftherios P. Diamandis
Henrietta M. Nielsen
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 5/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1266-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice

P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma

Acknowledgement to referees

Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma

Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice

Myopathy in Marinesco–Sjögren syndrome links endoplasmic reticulum chaperone dysfunction to nuclear envelope pathology